Document is current
Any future updates will be listed below
-
Authors
Cui, Zhifen https://orcid.org/0000-0002-5223-930X
Zeng, Cong https://orcid.org/0000-0003-4423-3634
Huang, Furong
Yuan, Fuwen
Yan, Jingyue
Zhao, Yue https://orcid.org/0000-0002-0110-0359
Zhou, Yufan https://orcid.org/0000-0002-8385-433X
Hankey, William
Jin, Victor X. https://orcid.org/0000-0002-8765-3471
Huang, Jiaoti
Staats, Herman F.
Everitt, Jeffrey I. https://orcid.org/0000-0003-0273-6284
Sempowski, Gregory D.
Wang, Hongyan
Dong, Yizhou https://orcid.org/0000-0001-5786-0659
Liu, Shan-Lu https://orcid.org/0000-0003-1620-3817
Wang, Qianben https://orcid.org/0000-0003-2636-7145
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (UC6-AI058607, R35 GM144117, R01 AI150473, U54 CA260582)
Duke University
- License Information
-
More Information
Article History
Received: 25 January 2022
Accepted: 24 June 2022
First Online: 25 July 2022
Competing interests
: Q.W., Z.C. and Y.D. are inventors on a patent (US Patent Application no. 17/626,482 entitled ‘Nanoparticle Systems for Targeted Delivery of CRISPR–Cas13 and Methods of Using Same’ filed 12 January, 2022, patent pending; European Patent Application no. 20840456.6 entitled ‘Nanoparticle Systems for Targeted Delivery of CRISPR–Cas13 and Methods of Using Same’ filed 12 January, 2022, patent pending) filed by Duke University that relates to the research reported in this paper. J.H. is a consultant for or owns shares in the following companies: Kingmed, MoreHealth, OptraScan, Genetron, Omnitura, Vetonco, York Biotechnology, Genecode, VIVA Biotech and Sisu Pharma and received grants from Zenith Epigenetics, BioXcel Therapeutics, Inc. and Fortis Therapeutics. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.
